GIOVANNI GUIDO CERRI
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Radiologia, Faculdade de Medicina - Docente
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina
LIM/44 - Laboratório de Ressonância Magnética em Neurorradiologia, Hospital das Clínicas, Faculdade de Medicina - Líder
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina
LIM/44 - Laboratório de Ressonância Magnética em Neurorradiologia, Hospital das Clínicas, Faculdade de Medicina - Líder
12 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 12
conferenceObject PET/MR characterization of mucinous versus nonmucinous components of rectal adenocarcinoma: a comparison of tumor metabolism and cellularity(2018) QUEIROZ, M.; BARBOSA, F. G.; NAVES, A.; DREYER, P.; MARIN, J. G.; ORTEGA, C.; CERRI, G. G.; BUCHPIGUEL, C.- Organization of the cancer network in SUS: evolution of the care model(2018) MADI, Marisa Riscalla; CERRI, Giovanni GuidoIn the current context of epidemiological transition, demographic changes, changes in consumption and lifestyle habits, and pressure on care costs and organized health systems for acute conditions, the Integrated Care Model by Shortell has become a conceptual reference in the search for new methods to manage chronic conditions by focusing on the health conditions of a given population that must be addressed by a set of institutions organized into networks. Within the last 15 years, cancer has gone from the third- to the second-leading cause of death in the State of Sao Paulo and has shown a gradual increase in the number of new cases; it has thus become a relevant issue for public health and health management. The model adopted by the State for the organization of the cancer care network was the motivation for this study, which aimed to evaluate the evolution of the model of care for cancer patients within the Unified Health System (Sistema Unico de Saude) based on the integrated care model. Since 1993, the year that cancer was first considered highly complex in the Sistema Unico de Saude by the Ministry of Health, it has been possible to observe a progressive orientation towards the integral and integrated care of patients with cancer. In the State of Sao Paulo, the active participation of qualified service providers through a Technical Reference Committee showed that experts could contribute to the definition of public policies, thereby providing a technical base for decision making and contributing to the development of clinical management.
conferenceObject Clinical workflow of PET/MR for primary staging of rectal cancer(2018) QUEIROZ, M.; BARBOSA, F. G.; ORTEGA, C.; FERREIRA, F.; MORAES, M.; CERRI, G. G.; BUCHPIGUEL, C.- Positron emission tomography/magnetic resonance imaging (PET/MRI): An update and initial experience at HC-FMUSP(2018) QUEIROZ, Marcelo A.; BARBOSA, Felipe de Galiza; BUCHPIGUEL, Carlos Alberto; CERRI, Giovanni GuidoThe new technology of PET/MRI is a prototype of hybrid imaging, allowing for the combination of molecular data from PET scanning and morphofunctional information derived from MRI scanning. Recent advances regarding the technical aspects of this device, especially after the development of MRI-compatible silicon photomultipliers of PET, permitted an increase in the diagnostic performance of PET/MRI translated into dose reduction and higher imaging quality. Among several clinical applications, PET/MRI gains ground initially in oncology, where MRI per se plays an essential role in the assessment of primary tumors (which is limited in the case of PET/CT), including prostate, rectal and gynecological tumors. On the other hand, the evaluation of the lungs remains an enigma although new MRI sequences are being designed to overcome this. More clinical indications of PET/MRI are seen in the fields of neurology, cardiology and inflammatory processes, and the use of PET/MRI also opens perspectives for pediatric populations as it involves very low radiation exposure. Our review aimed to highlight the current indications of PET/MRI and discuss the challenges and perspectives of PET/MRI at HC-FMUSP.
- Safety and Efficacy of Low-Level Laser Therapy in Autoimmune Thyroiditis: Long-Term Follow-Up Study(2018) HOFLING, Danilo Bianchini; CHAVANTES, Maria Cristina; BUCHPIGUEL, Carlos Alberto; CERRI, Giovanni Guido; MARUI, Suemi; CARNEIRO, Paulo Campos; CHAMMAS, Maria CristinaIntroduction. A randomized clinical trial (RCT) was performed to evaluate the efficacy of low-level laser therapy (LLLT) for hypothyroidism induced by chronic autoimmune thyroiditis (CAT). Objective. The objective was to assess the safety and actions of LLLT 6 years after completion of the RCT. Materials and Methods. Forty-three participants were invited to participate in this study 6 years after completion of the RCT. Twenty-five were subjected to LLLT (group L), and 18 were subjected to placebo (group P). Primary outcome measure: frequency of thyroid nodules, which were subjected to fine-needle aspiration biopsy. Secondary outcome measures: dose of levothyroxine required to treat hypothyroidism, thyroid peroxidase antibodies (anti-TPO), and anti-thyroglobulin antibodies (anti-Tg). Results. In group L, a nodule was observed in three patients, who all had a Bethesda II classification. In group P, a nodule was also observed in three patients, with two classified as Bethesda II and one as Bethesda III. The levothyroxine dose required by group L was significantly lower than that required by group P (P = 0 002). The anti-TPO and anti-Tg levels did not differ between the groups. Conclusion. LLLT, by the methods described, has been shown to be safe for the treatment of hypothyroidism resulting from CAT.
bookPart Prefácio do Prof. Dr. Giovanni Guido Cerri(2018) CERRI, Giovanni Guido- Clinical perspectives of PSMA PET/MRI for prostate cancer(2018) BARBOSA, Felipe de Galiza; QUEIROZ, Marcelo Araujo; NUNES, Rafael Fernandes; MARIN, Jose Flavio Gomes; BUCHPIGUEL, Carlos Alberto; CERRI, Giovanni GuidoProstate cancer imaging has become an important diagnostic modality for tumor evaluation. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has been extensively studied, and the results are robust and promising. The advent of the PET/magnetic resonance imaging (MRI) has added morphofunctional information from the standard of reference MRI to highly accurate molecular information from PET. Different PSMA ligands have been used for this purpose including (68)gallium and (18)fluorine-labeled PET probes, which have particular features including spatial resolution, imaging quality and tracer biodistribution. The use of PSMA PET imaging is well established for evaluating biochemical recurrence, even at low prostate-specific antigen (PSA) levels, but has also shown interesting applications for tumor detection, primary staging, assessment of therapeutic responses and treatment planning. This review will outline the potential role of PSMA PET/MRI for the clinical assessment of PCa.
- Magnetic resonance imaging assessment of the normal knee anterolateral ligament in children and adolescents(2018) HELITO, Camilo Partezani; HELITO, Paulo Victor Partezani; LEO, Renata Vidal; LOUZA, Isabel Curcio Felix; BORDALO-RODRIGUES, Marcelo; CERRI, Giovanni GuidoObjective To characterize the anterolateral ligament (ALL) in normal knees of pediatric patients by magnetic resonance imaging (MRI) and to establish the age at which it is possible to visualize its presence and whether there are differences between male and female populations. Materials and methods MRI scans of patients younger than 18 years were retrospectively evaluated. The exams were performed in 1.5-T scanners. The ALL was characterized dichotomously as visualized or not visualized based on the assessment criteria of this structure in adult patients. The characterization of the ALL was divided according to sex and age. Results A total of 363 knee MRI scans were evaluated, 200 from male and 163 from female patients. The ALL was more frequently visualized in coronal sequences. The mean ALL visualization in pediatric patients was 69.4% and was lower in younger patients and higher in patients close to 18 years. It was not possible to visualize the ALL in female patients younger than 7 years or in male patients younger than 6 years. In patients between 17 and 18 years of age, the ALL was visualized in 100% of cases in both sexes. Conclusions Visualization of the ALL increased with age in both sexes. Only after age 13 in females and age 15 in males was visualization of the ALL close to 70%; thus, below these ages, we believe that the characterization of this structure with conventional protocols is still imprecise.
conferenceObject PET/MR for staging rectal cancer: a comparison to conventional staging with pelvic MR and thoracoabdominal CT(2018) QUEIROZ, M.; BARBOSA, F. G.; ORTEGA, C.; FERREIRA, F.; MORAES, M.; BLASBALG, R.; NAHAS, S.; CERRI, G. G.; BUCHPIGUEL, C.conferenceObject Diagnostic performance of PET/MR in identifying high-risk primary rectal cancer patients(2018) QUEIROZ, M.; BARBOSA, F. G.; ORTEGA, C.; FERREIRA, F.; MORAES, M.; BLASBALG, R.; CERRI, G. G.; BUCHPIGUEL, C.